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Summary: Specific binding of [125I]insulin to isolated erythrocytes from four groups of women was investigated:
(A) pregnant subjects between weeks 38 and 40 of pregnancy (n = 18),
(B) postpartum subjects within 6 days after delivery (n = 20),
(C) normal women during the follicular phase of the menstrual cycle (n = 12) and
(D) normal women during the luteal phase öf the menstrual cycle (n = 11). *
Speciflc [125I]insulin binding (fraction), fasting plasma glucose concentrations (mmol/1) and the corresponding
insulin concentrations (mU/1) were
0.074 ± 0.012 / 4.00 ± 0.58 / 29.4 ± 21.4 for group A,
0.065 ± 0.016 / 4.40 ± 0.75 / 41.5 ± 26.2 for group B,
0.052 ± 0.008 / 4.58 ± 0.62 / 6.7 ± 4.0 for group C and
0.054 ±0.011/4.49 ± 0.63 / 8.3 ± 5.9 for group D.
By using a modified Scatchard analysis, statistically significant differences were observed between the receptor
affinities of the groups A aiid D, B and D, A and C.
The receptor affinities and concentrations were not significantly different between the follicular and the luteal
phases. From the data, no inverse correlation between the plasma insulin concentration and receptor binding was
seen, i.e. the phenömenon of downiegulation pf insulin receptor concentration with hyperinsulinaemia seemed not
to apply to erythrocytes.
The present results suggest that insulin binding to erythrocytes is mpdulated preferably or even exclusively by an
alteration of receptor affinity and that short-term chariges in insulin binding to erythroeytes are not caused by an
alterätion of receptor concentration.
Vergleich der Bindung von Insulin an Erythrocyten während und nach Schwangerschaft und in der Proliferations-
und der Sekretionsphase des Menstruations-Cyclus
Zusammenfassung: Die Bindung von [125I]Insulin an Erythrocyten wird bei vier Gruppen von Frauen untersucht:
Ä Schwangere in der 38.—40. Schwapgerschäftswöche (n = 18),
B Frauen innerhalb von 6 tagen nach Entbindung (n = 20),
C Frauen in der follifculären Cyclusphase (n = 12) und
D Frauen in der lutealen Cyclusphase (n = 11).
Die spezifische Bindung des [125I]Insulins (Anteil), die Plasma-Glucose-Konzentration (mmol/1) und die zugehörige
Insulinkonzentration (mU/1) sind für die vier Gruppen:
A (0,074 ± 0,012 / 4,00 ± 0,58 / 29,4 ± 21,4),
B (0,065 ± 0,016 / 4i40 ± 0',75 / 41,5 ± 26,2),
C (0,052 ±€,008 / 4,58 ± 0,62 / 6,7 ± 4,0) und
D (0,054 ±0,011/4,49 ± 0,63 / 8,3 ± 5,9).
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Mit Hilfe einer modifizierten Scatchard-Analyse wird gezeigt, daß statistisch signifikante Unterschiede zwischen den
Receptor-Affinitäten der Gruppen A und D, B und D sowie A und C existieren.
Die Differenzen der Receptor-Affinitäten und -Konzentrationen zwischen follikülärer und lutealer Cyclusphase sind
nicht signifikant. Zwischen der Insulin-Konzentration im Plasma und der Bindung des [125I]Insulins an den Receptor
besteht kein umgekehrt proportionaler Zusammenhang, d.h. das Phänomen der Downregulätion der Receptor-
Konzentration scheint für den Erythrocyten nicht zuzutreffen.
Die Resultate deuten daraufhin, daß am Erythrocyten die Bindung von Insulin bevorzugt oder ausschließlich durch
eine Änderung der Receptor-Affinität moduliert wird und daß kurzzeitige Fluktuationen in der Insulin-Bindung
offensichtlich nicht durch Veränderungen der Receptor-Konzentrationen bewirkt werden.
Introduction
Hormone binding to specific receptors locäted on the
plasma membrane of a target cell is believed to be the
first step in the sequence of events resulting in a definite
biological response (1—3). The magnitude of this response
depends on the hormone concentration, the receptor
concentration and the affinity of the receptor, whereby
alterations in any one of these can alter the biological
response. Insulin receptors have been defined in human
mononuclear cells (4—8) adipocytes (2, 5), placental
cells (9, 10), cultured lymphocytes (l 1), hepatocytes
(12), cultured fibroblasts (11), myocytes (13), gjanulo-
cytes (14), reticulocytes (15) and erythrocytes (11,
16-37).
Insulin action has been studied at the cell receptor
level, and the insulin binding and therefore insulin
sensitivity, has been shown to be altered in a number
of pathological states (2, 4-7,9,12,13,16, 20, 27,
31,38—42). The insulin receptor characteristics of the
human erythrocytes were shown to be similar to those
of other tissue ceUs (l, 2, 8,10, 12,13, 16, 20, 24).
Parallel alterations of insulin receptors of cells of various
body tissues and monocytes on one hand (40) and of
monocytes and erythrocytes on the other hand (27,
31,33,38,41,42) have led to the conclusion that
erythrocytes thus can be considered äs representätive
of insulin receptors on the cells of other body tissues.
Furthermore, it has been proposed that insulin binding
to human erythrocytes is a general measure of the
insulin sensitivity of body tissues (16, 20, 31).
Insulin binding to receptors is not a fixed biological
process but is subject to modülation by alterations in
either receptor number or affinity (2,30,43). The
former was thought to occur only in long-term regu-
lation (4,44,45), but recently an insulin-induced recep-
tor loss mediated by internalization has been suggested
(3) to explain a rapid downregulation of the insulin
plasma membrane receptors in the presence of high
hormone concentrations (46). Acute alterations in
insulin binding seem to be most commonly caused
by changes in receptor affinity (4,44,45,47,48),
The most populär method of graphical analysis of equi-
librium binding data is the one described by Scatchard
(49-52) to decide whether receptor concentration or
affinity is altered. Binding data at equilibrium, however,
do not distinguish between multiple classes of indepen-
dent sites, negative coopefativity in binding or both
multiple classes of cooperativejy interacting sites. Umtil
nöw the negative cooperativity mödel has been proposed
for the insulin receptor (49) and it is generally used to
explain the curvilinear Scatchard plots of insulin binding
data, though in the past two yeärs several repöfts have
questioned this concept (53), Fürthermore, from the
literature one can öbserve a peculiar correlation between
the highest ligänd concentrations chosen by the investi-
gator for extrapolation of tlie Scatchard plqt tö pf öVide
an abscissa intercept and the calculated number of
binding sites per cell derived frofn this intercept (fig. 1),
There is no definite criterion to decide the highest total
ligänd concentration for extrapolation of the terminal
slope of the Scatchard plot to proVide the total receptor
concentration. Each investigätor has therefore chosen
his own concentration, with the resült that a variety of
values for the number öf receptors (between 10 and
2000/normal efythrocyte) has been described in the
literatüre (fig. 1).
From ouf reeent findings on the influence of the non-
specific binding (54) on Scatchard plot data, we decided
to use the initial part of the Scatchard plot only for the
calculation of binding parameters.
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Fig. 1. Number öf insulin receptor sites per erythrocyte
(ordinate) and highest total ligänd concentration
(abscissa) used to provide the maximal amount of
o insulin bound according to the Scatchard plot.
Each circle represents data from literature; the refer-
ence numbers are enclosed. ,*
1ÖOOQ
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The Insulin receptor may be altered in many common
situations, s well s in rare disorders, or situations ac-
companied by Insulin resistance such s diabetes (2,20,
32, 55), obesity (4), acromegaly (56), acanthosis
nigricans (7), anorexia nervosa (27,42), uraemia (57),
ataxia telangiectasia (6), pregnancy (9,34,35, 58) and
during the menstrual cycle (33, 59,60).
By incl ding the modified Scatchard analysis, the present
study is an attempt to elucidate an inter-relationship
between the known insulin resistance during pregnancy
and its reflection in an altered insulin binding to erythro
cyte insulin receptors, by comparing the postpartum state,




Four groups of nonobese healthy females were studied:
A 18 women within two weeks before delivery
B 20 women within six days after delivery
C 12 women within the follicular phase of the menstrual cycle
D 11 women.within the luteal phase of the menstrual cycle.
None of the subjects were taking any drug known to affect
carbohydrate or insulin metabolism and none had a family
history of diabetes. About 12 ml blood were drawn into a
heparinized syringe (75 000 IU/1 blood) in the morning after
an overnight fast by venipuncture.
Reagents and equipment
Hoechst AG: porcine [12SI] insulin, specific activity 6.41
GBq/mg (175 mCi/mg), lyophil.;
Novo: porcine insulin, 10 X crystallized, l mg = 25 IU;
Serva: bovine albumin, lyophil., pure, 92% (CoAw-Fraction V);
EDTA · Naa - H2O;
E. Merck: Nad;KCl; Cad2 · 2H2O;Mga2 · 6 HiO;P(-»0-
glucose; Tris(hydroxymethyl)amino methane (TRIS);
barbital sodium; sodium acetate, anhydrous; sodium azide;
trichloroacetic acid; dibutyl phth jate, density 1.05 g/cm3;
Sigma: HEPES (N-2-hydroxyethylpiperazine*N'-2Tethane sulr
fonic acid);
Pharmacia: Ficpll-Paq e (100 ml contains: 5.7 g Ficoll 400,
9 g biatrizoate sodium), density 1.077 ± 0.001 g/cm3;
SephadexG-10;
Hoffmann-La R che: Liquemin 25000 (heparin sodium salt).
Buffer l: NaQ 50 rrimol/l; KQ 5 mmol/1; CaCl2 10 rnmol/1;
Mgd2 10 mmolAiTRIS 50 mmol/1; EDTA - Na2
2 mmolA; HEPES 50 mmol/1; Z)-glucose 10 mmol/1;
bovine serum albumin l g/l; pH 7.4 at 15 °C;
Buffer 2: barbital sodium 7.13 mmol/1; sodium acetate 11.8
mmol/1; sodium Chloride 138 mmol/1; sodium azide
15.4 mmol/1; bovine serum albunlin l g/l; pH 7.4.
Trichloroacetic acid in water 100 g/l;
Boehringer Mannheim: Test-Combination Glucose for the
determination of glucose by the glucose oxidase method;
Insulin was determined radioimmunologically s described
elsewhere (61).
glucose. The cell pellet was resuspended with two parts of
physiological saline, layered on 3 ml Ficoll-Paque and centri-
fuged at 400 g for 20 min at 20 °C. The supernatant incl ding
the upper layer of the erythrocyte phase was aspirated and the
cell pellet suspended in 2.5 parts of physiological saline, and
the above procedure repeated. The resulting cell pellet was then
suspended in 2.5 parts of buffer l to equilibrate the cells. After
centrifugation of the cell Suspension at 800 g for 15 min at
20 °C the buffer was aspirated and the cell pellet resuspended
in buffer l, so that the cell Suspension contained 3.3-6.6 · 1012/1.
Cell counting was performed using a Neubauer chamber.
Purification of [ 1257] insulin
The labelled hprmone was purified every three days using
a Sephadex G-ίθ column (15 X 1.4 cm) with buffer 2 at a speed
of 0.5 ml/min. 0.5 ml fractions were collected and the elution
pattern showed one peak at the fraction numbers 6-10 (insulin)
and another at the fraction numbers 25-35 (degradation pro-
ducts). Fractions 6 and 7 were combined and diluted with buffer
l t o give a concentration of 0.9 nmol/1.
Insulin Standard Solutions
Crystallized insulin was dissolved in 0.03 mol/1 HC1 and diluted
with buffer l to give various concentrations between 0.87 and
86 956 nmol/1.
Nonspecific binding and degradation o f insulin
Nonspecific binding, defined s the radioactivity associated
with erythrocyte pellets in the presence of an insulin concen-
tration of 17.4 μπιοΐ/ΐ, was subtracted from total binding to
yield specific binding. Nonspecific binding (fraction of total
radioactivity) was 0.0199 ±0.0023 for group A, 0.0203 ± 0.0063
for grpup B, 0.0187 ± 0.0033 for group C and 0.0193 ± 0.0032
for group D.
Insulin degradation was measured by examining the ability of
the unaltered [ 12S l j insulin and the B-chain to precipitate in the
presence of 50 g/l trichloroacetic acid (63). The fraction of
insulin degraded during inc bation was calculated by
Fraction f insulin degraded = (fraction of soluble activity in the
supernatant t =3 h — fraction of soluble activity in the super-
-... ..
Ϊ. 00 — Jfraction of soluble activity in the supernatantt = Q
The factor 1.5 accounts for the iqdine ratio of A- to B-chain of
2 to l (64). The fraction pf insulin degraded did not differ
between the subject groups and averaged 0.0456 ± 0.0223.
Insulin binding studies
400 μΐ erythrocytes (3.3 - 6.6 · 1012/1 buffer 1) were incubated
with 50 μΐ (125Ilinsulin solution (0.9 nmolA buffer 1) and 50 μΐ
insulin Standard Solutions (0.87 - 86 956 nmolA buffer 1) or
50 μΐ buffer l in a water bath at 15 °C with shaking (60 min'1)
for 3 hours. After incub tion, 200 μΐ duplicate aliquots were
tr nsferred to prechilled Eppendorf tubes containing 250 μΐ of
buffer l and 250 μΐ of dibutyl phthalate. The tubes were centri-
fugedat 12 000 £ for 1.5 min and the total radioactivity of each
tube counted in a gamma counter until 10 000 counts had been
acc mulated. The supernatants were then aspirated with a
Pasteur pipette, leaving about 50 μΐ of dibutyl phthalate on the
pellet. The tips of the tubes were cut off with a heated scalpel
and counted for 10 min.
Erythrocyte preparations
The preparation of human erythrocytes was performed according
the procedures of yum (62) and Gambhir (23) with slight
modifications. After centrifugati n of the heparinized blood
samples at 800 g for 10 min at room temperature the plasma
was aspirated, frozen and saved for the assays of insulin and
Data analyses
The fraction of radioactivity bound was determined by
Fraction B
_ erythrocyte pellet radioactivity
total radioactivity in 200 μΐ of the incubated cell Suspension
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The fraction of specific insulin bound at each conceritration of
unlabelled insulin was determined by subtracting the fraction of
[12SIJinsulin bound in the presence of 17.4 /l insulin from
the total fraction of i125 IJ insulin bound at each concentration of
unlabelled insulin.
The amount of insulin specifically bound was normalized to a
celi concentration of 4 · 1012/1.
The data on steady state binding of [125Ilinsulin to its receptor
are presented in two ways that emphasize different quantitative
aspects of the binding interaction: the fraction of specifically
bound [125 II insulin is plotted äs a function of the log total
insulin concentration, and the bound tö free ratio (B/F) of
[125I]insulin is plotted äs a function of bound hormone
(Scatchard plot).
Individual Scatchard plots were made for each subject, the slöpe
b of the initial part of the Scatchard plot (-Ka) was calculated
by regression analysis of the first seven points up to the 'critical
ligand concentration*; its intercept with the abscissa gave the
corresponding maximal amount of insulin bound (x0) from
which the number of receptor sites per cell Ro was calculated
by
R _ insulin bound (mol/1) · 6.023 · IQ23
cell concentration (cells/1)
R0 values of groups B, C and D were normally distributed, the
distribution for grqup A was positively skewed, but log (R0)
was normally distributed. Concerning the data of the slopes, arc
tan b values were compatible with a Gaussian distribution.
Statistical comparisons between R0 or log (R0) values and arc
tan b values, respectively, were calculated by Mann-Whitney 's
U-test and by Student** t-test.
Results and Discussion
The fasting insulin and blood glucose levels did not differ
for the follicular and the luteal phases whereas, äs already
known (65), the insulin levels of the pregnant and the
post-partum groups were higher and the blood glucose
levels were lower in comparison with the nonpregnant
states (tab. 1). Maximal specific [125I]insulin binding
was highest in group A followed by group B, whereas
the fraction of binding of the groups C and D were
lowest and nearly ideritical (tab. 2). The competition-
inhibition curves for the four different groups studied are
shown in figure 2. The half maximal competition concen-
tration was read from this plot (tab. 2). The Scatchard
plots (fig. 3) were curvilinear when considering the
entire ränge of total ligand concentrations investigated.
However, in view of our recent findings (54) and their
consequeiices, only the initial part of the Scatchard
plot up to 2 nmol/1 was used for calculation of the
affmity constants, K^, and the total number of receptor
sites, R0.
Tab. 1. Fasting insulin and plasma glucose concentratioris





Follicular phase (group C)
Luteal phase (group D)
Insulin
(mU/1)





















10'1 IQ0 101 102 03 1Ö4
insulin concentrgtiqn (nmol/ l)
Fig. 2. Comparisori öf insulin binding to erythiocytes.
Panel A: pregnancy (·), postpaftum state (o).
Panel B: follicular phase ( ), luteal phase (A).. _
Ordinate: fraction of specific [i2sljmsülin binding (x ± s).
Abscissa: total insulin concentration (nmol/l).
By equilibrium binding studies we demonsträted that
erythrocytes were saturated with specifically bound
insulin in the order of 0.1-0.2 nmol/l with 4 · 10U/1
erythrocytes, and that up to a total ligand concentra-
tion of äböüt 5 nmol/l and a cell count of 4 · l O12/l
more than 0.50 of the receptors were occupied. By
further increasing of the total ligand concentrations the
resulting data wefe more and more influenced by non-
specific binding, and the terrriinal piart of the Scatchard
plot became artefactual and could nötibe used for calcu^
lation pröcedüres. We therefore decided to use total
Tab. 2. Fiaction of specific [ 125I];insuliii binding to erythrocytes
(4 · 109 cells) (x ± s) and half maximal competition con-





Pregnancy (group A) 741 ± 0.0123 1.50
Postpartüm (group B) 0.0645 ± Ö.Ö162 1.83
Folücular phase (group C) 0.0520 ± 0.0084 2.00
Luteal phase (group D) 0.0535 ± 0.0107 2.05
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Fig. 3. Scatchard plots of the insulin binding data from figure 2.
Group A: pregnant state ·.
Group B: postpartum state o.
Group G: follicular phase .
Group D: luteal phase *.
Ordinate: bound/free ratio.
Abscissa: insulin specifically bound (nmol/l).
Inset: initial pait of the Scatchard plot on a larger scale.
ligand concentrations only up to 5 nmol/l with 4 - 1012/1
erythrocytes äs a 'critical ligand concentration' for the
investigation of specific insulin binding to erythrocyte
receptors (54).
By focussing on the initial part of the Scatchard plot,
curvilinearity disappeared and the character of this
hormone/receptor System was reduced to one binding
site with one characteristic affinity constant and a
receptor concentration of one characteristic order.
The slope b (—K^), the intercept with the abscissa (x0)
and the receptor number (Ro) were caiculated äs
described above; the results are summarized in table 3,
and the corresponding significances pf the differences
of Ka and x0 values are denoted in table 4.
The availability of reproducible methods to measure
cellular receptor characteristics has facilitated efforts
to understand the mecharüsms of hormone actipn.
Tab. 3. Insulin receptor affinity (Ka ± SKa), concentration
(X0 ± sX(>) aiid number of binding sites per erythro-




























In the case of Insulin, however, two difficulties seem
to prevent homogeneous results. Firstly, there has been
an increasing use of red blood cells for the investigation
of insulin receptor characteristics, and the erythrocyte
cannot synthesize receptor proteins; therefore, it can
probably be assumed that acute regulation mechanisms
may be restricted to affinity modulation. However,
there are several reports (33, 35, 36, 59, 60) which
explain even rapid changes in insulin binding by altera-
tions in receptor concentration evaluated by Scatchard
analysis and by the negative cooperativity model up
to high total ligand concentrations. The second uncer-
tainty arose from the ill defined conditions in using the
Scatchard plot to decide whether receptor concentra-
tion or affinity is altered. The higher the total ligand
concentrations chosen to provide an intercept of the
terminal slope with the abscissa, the higher is the cal-
culated number of receptors per cell (fig. 1). From this
observation one could conclude that the caiculated
number of receptor sites is limited ultimately by the
solubility of the hormone.
Furthermore, there is no agreement on insulin binding
to specific receptors during human pregnancy and during
the menstrual cycle. Beck-Nielsen et al. (55) found the
number of monocyte insulin receptors to be reduced
during pregnancy, Tsibris et al. (34) reported no differ-
ence of insulin receptor number and affinity between
pregnant and control groups for monocytes and for
erythrocytes. Soman et al. (66) described an increased
insulin binding to monocyte receptors during pregnancy,
wfiereasMoore et al. (35) found no receptor alteration
on erythrocytes during pregnancy. De Pirro et al. (59)
reported that insulin binding to monocytes was twofold
in the follicular phäse compared to the luteal phase. For
erythrocytes insulin binding was reported also to be
higher in the follicular phase in comparison with the
luteal phase. Bertolt et al. (33) explained this finding
by a decrease of the receptor concentration and an
increäse of the affinity during the follicular phase,
whereas no change in receptor concentration or affinity
should occur during the luteal phase. On the contrary,
Moore et al. (35) described that the decrease of insulin
binding during the luteal phäse is caused by a decrease in
receptor number with no change in affinity. Because
of these coiiflicting results and our previous finding of
Tab. 4. Statistical comparisons pf erythrocyte insulin receptor
affinities (Ka) and concentrations (x0) for four groups
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a 'critical ligand concentration' (54) it seemed necessary
to reinvestigate insulin binding to erythrocytes in the
prägnant and the postpartum state in comparison with
the follicular and the luteal phases of the menstrual
cycle.
Pregnancy has been shown to be accornpanied by insulin
resistance (65,67); the Interpretation of the mechanisms
underlying this interrelationship is discussed. Fasting
blood glucose levels of women in the third trimester of
pregnancy were found to be slightly lower than those of
normal menstruating women; fasting insulin levels were
found to be higher according to Moore et al. (35),
Tsibris et al. (34) and Spellacy et al. (68). Insulin and
blood glucose levels did not vary during the menstrual
cycle; these results are in agreement with those of
Bertoli et al. (33). Though the fasting insulin level of
the postpartum group remained elevated within six days
after delivery, the corresponding glucose level iiicreased
to concentrations comparable with those of the follicular
and the luteal phases. After parturition, blood glucose
levels seemed to normalize earlier than insulin levels.
Mean [125I]insulin binding was slightly lower for the
postpartum group in comparison to the pregnant groüp
(tab. 2). This fmding agreed v/itiiMoore et al. (35), but
our results indicated no significant alteratiön, either of
the receptor affinity (tab. 3 and 4) or of the receptor
concentration, claimed by Moore et al. (35), employing
the extended Scatchard plot and the average affinity
analysis. There was no significant difference in [125I]·
insulin binding between the follicular and the luteal
phases of the menstrual cycle (tab. 2, 3 and 4). This
is in contradiction to Bertoli et al. (33) and Moore et al.
(35) who reported higher insulin binding in the follicular
phase and who explained this difference by changes of
the receptor concentration. We suppose that this Inter-
pretation, which has been described earlier for mono-
cytes by De Pirro et al. (59), may not be applicable to
erythrocytes because it is poorly understood how
receptors can appear and disappear (or become masked)
in rhythmical two weekly fluctuations.
Tsibris et al. (34) found no difference in [125I]insulin
binding to erythrocytes in pregnancy and in the luteal
phase of the menstrual cycle, whereäsMoare et al. (35)
reported that insulin binding to erythrocytes was
highest in the follicular phase and in pregnancy and
both were significantly higher than insulin binding
during the luteal phase. Like Moore et al. (35) we found
insulin binding in the pregnant group higher than that in
the luteal phase (tab. 2), but our data from the modified
Scatchard analysis indicated a significant alteratiön in
receptor affinity, whereasAfoore et al. (35) described a
Variation in receptör concentration. Furthermore we
found that [125I]insulin binding in the pregiiäiit group
was higher than that in the follicular phase, and this was
cäused by an alteratiön of receptor affinity. Parturition
did not alter the insulin receptor characteristics; Ka and
R0 values of the groups A and B were very similar (tab.
3 and 4). Despite the high insulin levels (tab. 1) groups
A and B showed the highest iijsulin binding which was
based on high affinity constants but ünaltered' receptor
concentrations (tab, 2 an<I 3). We were therefore unable
to find the well-known inverse correlätion between
insulin binding and plasma insulin concentration for
erythrocytes, i.e. the well^documented downregulation
of insulin receptor concentration on plasrna membranes
of other cell types cäused by hyperinsuliriäemia. Like
Tsibris et al. (34) we found that insulin receptors did
not decrease during pregnancy, despite hyperinsulin-
aemia, and suggest that sorrie factors exist during
pregnaney that modüläte insulin receptors in a positive
manner, äs seen by an increased affinity and partiäUy
by an increased receptor concentration (tab. 3 and 4).
In summary, the current results indieate that erythro-
cytes seem to modüläte insulin binding chiefly or
exclusively by an alteratiön of receptor affinity, and
that short-term changes of insulin binding to erythro-
cytes could not be explained by an alteration pf receptor
concentration.
References
1. Jarett, L. (1979) Human Pathol. 20t 301-311.
2. Olefsky, J. M. (1976) Diabetes 25, 1154-1165.
3. Corden, Ph., Carpentier, J.-L., Freychet, P. & Orci, L. (1980)
Diabetologia 18, 263-274.
4. Bar, R. S., Corden, P. & Roth, J. (1976) J. Clin. Invest. 58,
1123-1149.
5. Olefsky, J. M. (1976) J. Clin. Invest. 57,1165-1172.
6. Bar, R. S., Lewis, W. R., Rechter, M. M., Harrison, L. C.,
Siebert, C., Podskalny, J., Roth, J. & Muggeo, M. (1978) N.
Engl. J. Med. 298,1164-1171.
7. Kahn, C. R., Füer, J. S., Bar, R. S., Archer, J. A.; Corden, P.,
" Martin, M. M. & Roth, J. (1976) N. Engl. J. Med. 294,
739-745.
8. Schwartz, R. H., Bianco, A. R., Handwerger, B. S. & Kahn,
C. R. (1975) Proc. Natl. Acad. Sei. U.S.A. 72,474-478.
9. Harrison, L. C., Billington, T., Clark, S., Nichols, R., East, I.
& Martin, F. 1. R. (1977) J. Clin. Endocrinol. Metab. 44,
206-209.
10. Harrison, L. G, BiHingtori, T., East, I. & Nichols, R. J, (1978)
Endocrinology 102,1485-1495.
11. Gavin, J. R., Roth, J., Jen, P. & Freychet, P. (1972) Proc.
Nat. Acad. Sei. U.S.A. 69, 747-751.
12. Freychet, P., Roth, J. & Neville Jr., D. M. (1971) J. Clin.
Invest. 50, 34 A.
13. Forgue, M. E. & Freychet, P. (1?75) Diabetes 24, 715-723.
14. Fussganger, R. D., Kahn, C. R., koth, J. & De-Meyts, P.
(1976) J. Biol. Chem. 257,2761-2769.
15. Ivarsson, S. A. & Thorell, J. L (1981) Clin. Chem: 27,
347-348.
16. Nerurkar, S. G. & Gambhir, K. K. (1979) Oin. Cheni. 25,
1672-1673.
17. De Pirro, R., Bertoli, A., Greco, A. V.s Fusco, A. & Lauio, R.
(1979) Acta Endocrinol. (Kbh.) ISuppl. 225,310.
18. Pedersen, O., Hj^Uund, E., Beck-Nie|sen, H. & Kromann, H.
(1981) New Engl. J. Med. 304,108^-1088.
19. Kappy, M. S. & Plptnick, L. (1979) Diabetes 28, 1001- 05.
J. Clin. Cherri. Clin. Biochem. / Vol. 20,1982 / No. 5
Dwenger, Mitzkat, Holle, Tost and Trautschold: Insulin binding to erythrocytes 279
20. Robinson, T. J., Archer, J. A., Gambhir, K. K., Hollis, Jr., 44.
V. W., Carter, L. & Bradley, C. (1979) Science 205,
200-202. 45.
21. De Pirro, R., Fusco, A., Spallone, L., Magnatta, R. & Lauro,
R. (1980) Diabetologia 19,118-122. 46.
22. Eng, J., Lee, L. & Yalow; R. S. (1980) Diabetes 29, 164-166.
23. Gambhir, K. K., Archer, J. A. & Carter, L. (1977) Clin. Chem. 47
23, 1590-1595. 48.
24. Gambhir, K. K., Archer, J. A. & Bradley, C. J. (1978) Diabe-
tes 27, 701-708. 49.
25. Yasuda, K. & Kitabchi, A. E. (1980) Diabetes 29, 811-814.
26. De Pirro, R., Fusco, A., Lauro, R., Testa, L, Ferreti, F. 50.
& De Martinis, C. (1980) Diabetes 29, 96-99. 51.
27. Wachslicht-Rodbard, H., Gross, H, A., Rodbard, D., Ebert,
M. H. & Roth, J. (1979) N. Engl. J. Med. 300, 882-887. 52.
28. Herzberg, V., Boughter, J. M., Carlisle, S. & Hül, D. E.
(1980) Nature 286, 279-280. 53.
29. Prager, R. & Schernthaner, G. (1981) Akt. Endokrinol. 2, 54.
109.
30. Insel, J. R., Koltermann, O. G., Saekow, M. & Olefsky, J. M. 55.
(1980) Diabetes 29,132-139.
31. Gambhir, K. K., Nerurkar, S. G., Cruz, I. A. & Hosten, A. O.
(1981) Biochem. Med. 25,62-73. 56.
32. Pedersen, O., Beck-Nielsen, H. & Heding, L. (1980) N. Engl.
J. Med. 302, 886-892. 57.
33. Bertoli, A. De Pirro, R., Fusco, A., Greco, A. V., Magnatta,
Rosanna & Lauro, R. (1980) J. Clin. Endocrinol. Metab. 50, 53.
246-250. 59.
34. Tsibris, J. C. M., Raynor, L. O., Buhi, W. C., Buggie, J.
& Spellacy, W. N. (1980) J. Clin. Endocrinol. Metab. 57, 60.
711-717.
35. Moore, P., Koltermann, O., Weyant, J. & Olefsky, J. M. 61.
(1981) J. Clin. Endocrinol, Metab. 52, 937-941.
36. Holle, A., Mangels, W., Dreyer, M., Kühnau, J. & Rüdiger, 62.
H. W. (1981) N. Engl. J. Med. 305, 563-566.
37. Hendricks, S. A., Lippe, B. M., Kaplan, S. A., Landaw, E. M., 63.
Hertz, D. & Scott, M. (1981) J. Clin. Endocrinol. Metab. 52, 64.
969-974.
38. Goldstein, S., Blecher, M., Binder, R., Perrino, P. V. 65.
& Recant, L. (1975) Endocrinol. Res. Commun. 2,
367-376.
39. Archer, J. A., Gorden, P., Gavin III, J. R., Lesniak, M. A. 66.
& Rpth, J. (1973) J. Clin. Endocrinol. Metab. 36,
627-633.
40. Blecher, M. (1979) Oin. Chem. 25,11-19. 67.
41. Gambhir, K. K., Archer, J. A., Robinson, T. & Carter, L.
(1978) Clin. Res. 23,415 A.
42. Somaii, V. & Feiig, P. (1979) Clin. Res. 27, 260 A. 68.
43. Roth, J., Kahn, C. R., Lesniak, M. A., Gorden, P., De
Meyts, P., Megyesi, K., Nevüle, D. M. & Archer, J. A.
(1976) Recent Prog. Horm. Res. 31, 95-126.
Koltermann, O. G., Saekow, M. & Olefsky, J. M. (1979)
J. Clin. Endocrinol. Metab. 48, 836-842.
Koltermann, O. G., Greenfield, M., Reaven, G. M., Saekow,
M. & Olefsky, J. M. (1979) Diabetes 28, 731-736.
Rezzino, V., Vigneri, R., Pliam, N. B. & Goldfine, I. D. (1980)
Diabetolo^a 19, 211-215.
Olefsky, J. M. (1976) J. Clin. Invest. 38, 1450-1460.
Muggeo, M., Bar, R. S. & Roth, J. (1977) J. Clin. Endocrinol.
Metab. 44,1206-1209.
De Meyts, P. & Roth, J. (1975) Biochem. Biophys. Res.
Commun. 66,1118-1126.
Scatchard, G. (1949) Ann. N.Y. Acad. Sei. 51, 660-672.
Berson, S. A. & Yalow, R. S. (1959) J. Clin. Invest. 38,1966
-1973.
De Meyts, P., Bianco, A. R. & Roth, J. (1976) J. Biol. Chem.
257, 1877-1888.
Levitzki, A. (1981) Nature 259,442-443.
Dwenger, A., Tost, P. & Trautschold, I. (1982) Fresenius Z.
Anal. Chem. 311, 471-472.
Beck-Nielsen, H., Kühl, C., Pedersen, O., Bjerre-Christensen,
C., Nielsen, T. T. & Klebe, J. G. (1979) J. Clin. Endocrinol.
Metab. 49, 810-814.
Muggeo, M., Bar, R. S., Roth, J., Kahn, C. R. & Gorden, P.
(1979) J. Clin. Endocrinol. Metab. 48, 17-25.
De Fronzo, R. A. & Alvestrand, A. (1980) Am. J. Nutrit.
33,1438-1445.
Posner, B. I. (1974) Diabetes 23, 209-217.
De Pirro, R., Fusco, A., Bertoli, A., Greco, A. V. & Lauro, R.
(1978) J. Clin. Endocrinol. Metab. 47,1387-1389.
De Pirro, R., Porte, F., Bertoli, A., Greco, A. V. & Lauro, R.
(1981) J. Clin. Endocrinol. Metab. 52, 29-33.
Dwenger, A., Tost, P. & Trautschold, I. (1977) J. din.
Chem. Clin. Biochem. 75, 593-602.
Böyum, A. (1968) Scand. J. Clin. Invest. 27 (Suppl. 97),
77-89.
Tomizawa, H. H. (1962) J. Biol. Chem. 237,428-431.
Brodal, B. P. (1971) Scand. J. Clin. Lab. Invest. 28,
287-293.
Feiig, P. (1975) Diabetes mellitus. In: Medicai Cornplications
During Pregnancy (Burrow, G. & Ferris, M. eds.), W. B.
Saunders Co. Philadelphia, p. 186.
Soman, V., Constan, D. & Feiig, P. (1979) Program and .
Abstract of the 61th Annual Meeting of the Endocrine
Society, Anaheim CA, abstract 184, p. 118.
William, R., Porte, D. (1974) The Pancreas. In: Textbook
of Endocrinology (William, R. ed.) W. B. Saunders Co.,
Philadelphia, p. 588.
Spellacy, W. N. & Goetz, F. C. (1963) N. Engl. J. Med.
268, 988-992.
Dr. rer. nat. Alex Dwenger





J. Cün. Chem. Clin. Biochem. / Vol. 20,1982 / No. 5

